Correlation between circulating levels of eculizumab, CH50, and outcomes in PNH patients treated with eculizumab
| Variables . | Eculizumab trough level . | |||
|---|---|---|---|---|
| <35 µg/mL . | 35-100 µg/mL . | 100-200 µg/mL . | >200 µg/mL . | |
| Number of samples | 19 | 140 | 124 | 70 |
| LDH, median (IQR) IU/L | 459 (402-516) | 462 (428-520) | 450 (377-492) | 467 (435-504) |
| N (%) >1.5 ULN | 3 (18) | 9 (7) | 6 (6) | 1 (2) |
| Hemoglobin, median (IQR) g/dL | 9.1 (8.7-9.4) | 9.6 (9.0-10.6) | 10.1 (9.8-10.8) | 10.3 (9.9-10.6) |
| Bilirubin, median (IQR) µM/L | 24 (21-26) | 22 (17-31) | 18 (15-20) | 17 (14-24) |
| ARC, median (IQR) ×103/L | 148 (139-165) | 181 (148-227) | 139 (112-198) | 110 (98-212) |
| Need for transfusion, N (%) | 2 (11) | 2 (1) | 1 (1) | 0 (0) |
| Blocked CH50, N (%) | 6 (32) | 55 (39) | 67 (54) | 47 (68) |
| Hemoglobinuria, N (%) | 5 (26) | 33 (24) | 27 (22) | 7 (11) |
| Abdominal pain, N (%) | 5 (26) | 13 (9) | 20 (17) | 1 (2) |
| Infection, N (%) | 0 (0) | 6 (6) | 6 (6) | 4 (7) |
| Variables . | Eculizumab trough level . | |||
|---|---|---|---|---|
| <35 µg/mL . | 35-100 µg/mL . | 100-200 µg/mL . | >200 µg/mL . | |
| Number of samples | 19 | 140 | 124 | 70 |
| LDH, median (IQR) IU/L | 459 (402-516) | 462 (428-520) | 450 (377-492) | 467 (435-504) |
| N (%) >1.5 ULN | 3 (18) | 9 (7) | 6 (6) | 1 (2) |
| Hemoglobin, median (IQR) g/dL | 9.1 (8.7-9.4) | 9.6 (9.0-10.6) | 10.1 (9.8-10.8) | 10.3 (9.9-10.6) |
| Bilirubin, median (IQR) µM/L | 24 (21-26) | 22 (17-31) | 18 (15-20) | 17 (14-24) |
| ARC, median (IQR) ×103/L | 148 (139-165) | 181 (148-227) | 139 (112-198) | 110 (98-212) |
| Need for transfusion, N (%) | 2 (11) | 2 (1) | 1 (1) | 0 (0) |
| Blocked CH50, N (%) | 6 (32) | 55 (39) | 67 (54) | 47 (68) |
| Hemoglobinuria, N (%) | 5 (26) | 33 (24) | 27 (22) | 7 (11) |
| Abdominal pain, N (%) | 5 (26) | 13 (9) | 20 (17) | 1 (2) |
| Infection, N (%) | 0 (0) | 6 (6) | 6 (6) | 4 (7) |